OCUL
VENTE TOTALE: 21 649 titres (~233 159,73 $ US)
- Insiders
- Dugel Pravin
- Total bought
- —
- Total sold
- $233,160
- Last activity
- 2026-08-24
- Last synced
-
2026-08-30 10:16:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-28
OCUL presents a deeply unfavorable risk/reward profile: severe financial distress with ~-500% operating margins and rapid cash burn overwhelms the modest positive signal from the AXPAXLI NDA pipeline progress.
The first sentence of the analysis written for OCUL on 2026-08-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 87.3% | 91.2% | 91.0% | 91.2% | 89.9% | |
| Ebit Margin | -490.3% | -282.4% | -118.7% | -124.3% | 0.3% | |
| Ebitda Margin | -482.0% | -276.4% | -113.6% | -120.2% | 5.8% | |
| Operating Profit Margin | -521.0% | -269.6% | -141.0% | -152.7% | -179.3% | |
| Pretax Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Continuous Operations Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Net Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Bottom Line Profit Margin | -513.2% | -303.7% | -148.8% | -155.9% | -184.4% | |
| Current Ratio | 15.394 | 10.664 | 6.655 | 4.129 | 7.264 | |
| Quick Ratio | 15.324 | 10.590 | 6.589 | 4.066 | 7.216 | |
| Solvency Ratio | -1.702 | -1.331 | -0.483 | -0.605 | -0.035 | |
| Cash Ratio | 14.507 | 9.482 | 5.611 | 3.258 | 6.233 | |
| Price To Earnings Ratio | -8.549 | -7.000 | -4.092 | -2.702 | -6.638 | |
| Price To Earnings Growth Ratio | -0.522 | -0.587 | -0.851 | 2.837 | 0.113 | |
| Forward Price To Earnings Growth Ratio | -0.522 | -0.587 | -0.851 | 2.837 | 0.113 | |
| Price To Earnings Diluted Ratio | -8.549 | -7.000 | -4.373 | -2.897 | -7.112 | |
| Price To Earnings Diluted Growth Ratio | -0.522 | -0.357 | -0.848 | 2.839 | 0.115 | |
| Price To Book Ratio | 3.474 | 4.286 | 3.907 | 6.106 | 6.051 | |
| Price To Sales Ratio | 43.863 | 21.210 | 6.092 | 4.195 | 12.234 | |
| Price To Free Cash Flow Ratio | -10.480 | -9.941 | -4.665 | -3.412 | -7.978 | |
| Price To Operating Cash Flow Ratio | -11.095 | -10.036 | -5.069 | -3.624 | -8.123 | |
| Debt To Assets Ratio | 0.099 | 0.165 | 0.331 | 0.431 | 0.288 | |
| Debt To Equity Ratio | 0.122 | 0.240 | 0.915 | 1.817 | 0.670 | |
| Debt To Capital Ratio | 0.109 | 0.194 | 0.478 | 0.645 | 0.401 | |
| Long Term Debt To Capital Ratio | 0.102 | 0.178 | 0.451 | 0.604 | 0.369 | |
| Financial Leverage Ratio | 1.235 | 1.452 | 2.766 | 4.220 | 2.328 | |
| Working Capital Turnover Ratio | 0.092 | 0.213 | 0.395 | 0.391 | 0.226 | |
| Operating Cash Flow Ratio | -4.033 | -3.257 | -2.013 | -1.898 | -2.489 | |
| Operating Cash Flow Sales Ratio | -3.954 | -2.113 | -1.202 | -1.157 | -1.506 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.059 | 1.010 | 1.087 | 1.062 | 1.018 | |
| Debt Service Coverage Ratio | -17.048 | -12.974 | -5.858 | -8.816 | 0.381 | |
| Interest Coverage Ratio | -22.815 | -12.652 | -7.266 | -11.201 | -11.698 | |
| Short Term Operating Cash Flow Coverage Ratio | -72.731 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.568 | -1.777 | -0.842 | -0.927 | -1.111 | |
| Capital Expenditure Coverage Ratio | -17.059 | -104.563 | -11.538 | -16.044 | -54.899 | |
| Dividend Paid And Capex Coverage Ratio | -17.059 | -104.563 | -11.538 | -16.044 | -54.899 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.469 | -5.877 | -3.668 | -2.875 | 168.286 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.3% | ▼-3.9% | ▼-2.8% |
| Ebit Margin | -490.3% | ▼-208.0% | ▼-287.2% |
| Ebitda Margin | -482.0% | ▼-205.6% | ▼-284.7% |
| Operating Profit Margin | -521.0% | ▼-251.5% | ▼-268.3% |
| Pretax Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Continuous Operations Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Net Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Bottom Line Profit Margin | -513.2% | ▼-209.5% | ▼-252.0% |
| Current Ratio | 15.394 | ▲4.731 | ▲6.573 |
| Quick Ratio | 15.324 | ▲4.734 | ▲6.567 |
| Solvency Ratio | -1.702 | ▼-0.371 | ▼-0.871 |
| Cash Ratio | 14.507 | ▲5.026 | ▲6.689 |
| Price To Earnings Ratio | -8.549 | ▼-1.549 | ▼-2.753 |
| Price To Earnings Growth Ratio | -0.521 | ▲0.065 | ▼-0.720 |
| Forward Price To Earnings Growth Ratio | -0.521 | ▲0.065 | ▼-0.720 |
| Price To Earnings Diluted Ratio | -8.549 | ▼-1.549 | ▼-2.563 |
| Price To Earnings Diluted Growth Ratio | -0.521 | ▼-0.165 | ▼-0.767 |
| Price To Book Ratio | 3.474 | ▼-0.812 | ▼-1.291 |
| Price To Sales Ratio | 43.863 | ▲22.653 | ▲26.344 |
| Price To Free Cash Flow Ratio | -10.480 | ▼-0.540 | ▼-3.185 |
| Price To Operating Cash Flow Ratio | -11.095 | ▼-1.059 | ▼-3.505 |
| Debt To Assets Ratio | 0.099 | ▼-0.067 | ▼-0.164 |
| Debt To Equity Ratio | 0.122 | ▼-0.118 | ▼-0.631 |
| Debt To Capital Ratio | 0.109 | ▼-0.085 | ▼-0.257 |
| Long Term Debt To Capital Ratio | 0.102 | ▼-0.077 | ▼-0.239 |
| Financial Leverage Ratio | 1.235 | ▼-0.217 | ▼-1.165 |
| Working Capital Turnover Ratio | 0.092 | ▼-0.122 | ▼-0.172 |
| Operating Cash Flow Ratio | -4.033 | ▼-0.776 | ▼-1.295 |
| Operating Cash Flow Sales Ratio | -3.954 | ▼-1.840 | ▼-1.967 |
| Free Cash Flow Operating Cash Flow Ratio | 1.059 | ▲0.049 | ▲0.011 |
| Debt Service Coverage Ratio | -17.048 | ▼-4.074 | ▼-8.185 |
| Interest Coverage Ratio | -22.815 | ▼-10.163 | ▼-9.689 |
| Short Term Operating Cash Flow Coverage Ratio | -72.731 | ▼-72.731 | ▼-58.185 |
| Operating Cash Flow Coverage Ratio | -2.568 | ▼-0.791 | ▼-1.123 |
| Capital Expenditure Coverage Ratio | -17.059 | ▲87.504 | ▲23.761 |
| Dividend Paid And Capex Coverage Ratio | -17.059 | ▲87.504 | ▲23.761 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.469 | ▼-0.592 | ▼-36.348 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.27B | $1.35B | $356.0M | $216.0M | $532.5M | |
| Enterprise value | $1.62B | $1.04B | $243.6M | $178.0M | $427.3M | |
| EV / Sales | 31.18x | 16.25x | 4.17x | 3.46x | 9.82x | |
| EV / Op. cash flow | -7.89x | -7.69x | -3.47x | -2.99x | -6.52x | |
| EV / Free cash flow | -7.45x | -7.61x | -3.19x | -2.81x | -6.40x | |
| EV / EBITDA | -6.47x | -5.88x | -3.67x | -2.88x | 168.29x | |
| Net debt / EBITDA | 2.63x | 1.80x | 1.69x | 0.61x | -41.43x | |
| Current ratio | 15.39x | 10.66x | 6.66x | 4.13x | 7.26x | |
| Income quality | 0.77x | 0.70x | 0.87x | 0.84x | 10.00x | |
| Graham net-net | $3 | $2 | $1 | $0 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 104.7% | 107.5% | 116.3% | 111.0% | -5553.4% | |
| Working capital | $731.3M | $399.6M | $197.3M | $98.2M | $165.0M | |
| Invested capital | $755.6M | $415.0M | $215.6M | $116.1M | $176.8M | |
| Return on assets | -32.9% | -42.3% | -32.0% | -47.6% | -3.2% | |
| Operating ROA | -42.7% | -48.4% | -41.1% | -44.4% | -33.4% | |
| Return on tangible assets | -32.9% | -42.3% | -32.0% | -47.6% | -3.2% | |
| Return on equity | -40.6% | -61.4% | -88.6% | -200.8% | -7.4% | |
| Return on invested capital | -35.5% | -41.0% | -37.7% | -65.8% | -43.3% | |
| Return on capital employed | -35.7% | -41.2% | -37.9% | -66.7% | -43.7% | |
| Earnings yield | -11.7% | -14.3% | -22.7% | -32.9% | -1.2% | |
| Free cash flow yield | -9.5% | -10.1% | -21.4% | -29.3% | -12.5% | |
| Capex / Op. cash flow | -5.9% | -1.0% | -8.7% | -6.2% | -1.8% | |
| Capex / Depreciation | 277.8% | 34.0% | 204.1% | 176.1% | 49.3% | |
| Capex / Sales | 23.2% | 2.0% | 10.4% | 7.2% | 2.7% | |
| SG&A / Sales | 228.3% | 160.4% | 127.5% | 140.1% | 154.1% | |
| R&D / Sales | 380.3% | 200.3% | 104.5% | 103.8% | 115.1% | |
| Stock comp / Sales | 83.3% | 52.0% | 30.5% | 32.9% | 34.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 216d | 186d | 163d | 151d | 177d | |
| Days payables outstanding | 231d | 271d | 303d | 412d | 380d | |
| Operating cycle | 414d | 383d | 323d | 310d | 281d | |
| Cash conversion cycle | 183d | 112d | 19d | -102d | -100d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+68.2%EV / Sales ▲+91.9%EV / EBITDA ▼-10.1%EV / Op. cash flow ▼-0.200Earnings yield ▲+0.026
Profitability
Return on equity ▲+0.207Return on assets ▲+0.093Return on invested capital ▲+0.055Return on capital employed ▲+0.056Operating ROA ▲+0.057Income quality ▲+0.074Tax burden 0.000
Efficiency
Days sales outstanding ▲+30.358Days payables outstanding ▼-40.290Operating cycle ▲+31.011Cash conversion cycle ▲+71.301Capex / Sales ▲+0.212R&D / Sales ▲+1.800
Balance-sheet strength
Current ratio ▲+4.731Net debt / EBITDA ▲+0.836Working capital ▲+331690000.000Invested capital ▲+340670000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+326.9%EV / Sales ▲+217.6%EV / EBITDA ▼-103.8%EV / Op. cash flow ▼-1.368Earnings yield ▼-0.105
Profitability
Return on equity ▼-0.332Return on assets ▼-0.297Return on invested capital ▲+0.078Return on capital employed ▲+0.080Operating ROA ▼-0.092Income quality ▼-9.233Tax burden 0.000
Efficiency
Days sales outstanding ▲+38.624Days payables outstanding ▼-149.771Operating cycle ▲+132.952Cash conversion cycle ▲+282.723Capex / Sales ▲+0.204R&D / Sales ▲+2.653
Balance-sheet strength
Current ratio ▲+8.131Net debt / EBITDA ▲+44.058Working capital ▲+566360000.000Invested capital ▲+578851000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-28 BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of the biopharmaceutical company''s stock, valued at approximately $190,278,000. BlackRock Inc. owned 8.82% of Ocular Therapeutix as of its most recent filing with
- 2026-08-18 Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
- 2026-08-17 Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
- 2026-08-13 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company''s new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient''s acceptance of employment with Ocular under Ocular''s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-08-13 California State Teachers Retirement System Increases Stock Position in Ocular Therapeutix, Inc. $OCUL California State Teachers Retirement System increased its holdings in Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 41.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,706 shares of the biopharmaceutical company''s stock after acquiring an additional 63,005 shares during the quarter. California
- 2026-08-07 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.
- 2026-08-05 Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI''s annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.
- 2026-08-03 Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.
- 2026-08-03 Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights Ocular''s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
- 2026-07-22 Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on the planned filing package.